ÌÇÐÄvlog´«Ã½

Narcolepsy Therapeutics Market Analysis

The Global Narcolepsy Therapeutics Market size is estimated at USD 3.80 billion in 2024, and is expected to reach USD 5.60 billion by 2029, growing at a CAGR of 8.04% during the forecast period (2024-2029).

The increasing prevalence of narcolepsy, rising narcolepsy awareness programs and services, and the presence of reimbursement policies regarding narcolepsy are significant drivers in the market. For instance, according to the journal published by the National Institute of Neurological Disorders and Strokes in January 2023, around 125,000 to 200,000 people suffered from narcolepsy in the United States in 2022. According to a January 2023 journal published by Healthline, an estimated 44.3 to 50 individuals per 100,000 in the United States were diagnosed with narcolepsy in 2022.

In addition, according to the article published by the Journal of Clinical Sleep Medicine in June 2022, an estimated 47 people per 100,000 were reported to have narcolepsy across Europe. In Germany, the incidence was estimated to be about 17.88 people per 100,000 in 2022. Such a high incidence of disorder leads to an increase in the demand and adoption of narcolepsy therapies, which is expected to drive the market's growth during the forecast period.

Market players' approval and commercialization of new drugs may also be crucial in driving market growth over the coming years. For instance, in June 2023, Avadel Pharmaceuticals PLC launched Lumryz, an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Thus, such strategic initiatives are expected to help the market to grow during the forecast period.

However, adverse effects and risks related to narcolepsy drugs and delayed diagnosis or misdiagnosis may hinder the market growth during the forecast period.

Narcolepsy Therapeutics Industry Segmentation

As per the scope of the report, narcolepsy is a long-term neurological disorder involving a decreased ability to regulate sleep-wake cycles. Symptoms include periods of excessive daytime sleepiness that last from seconds to minutes and can occur at any time. Treatment usually involves lifestyle changes, medications, and behavioral strategies.

The narcolepsy therapeutics market is segmented by type, product, and geography. By type, the market is segmented into cataplexy, without cataplexy, and secondary narcolepsy. By product, the market is segmented into central nervous system stimulants, sodium oxybate, tricyclic antidepressants, and other products. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (USD) for the above segments.